Beatson only UK site for pioneering prostate cancer trial
Dr Abdulla Alhasso MB ChB MRCP FRCR
12th February 2021
By Dr Abdulla Alhasso, Lead Clinician and UK Chief Investigator for the Clinical Study of the ProSpace™ Balloon System.
Radical Intensity modulated radiotherapy with image guidance is considered to be one of the standard treatment options for prostate cancer. However, it can be associated with both early and delayed side effects potentially resulting in rectal complications due to the anatomical proximity of the prostate and rectum. This can lead to long-term impact on quality of life and potential need for endoscopic assessment and surgical intervention in the future.
Prostate cancer is one of the commonest cancers in Scotland, so we were extremely proud to have been able to open this study to improve prostate cancer radiotherapy amid ongoing COVID-19 challenges in Glasgow late last year.
The ProSpace™ Balloon System study is trialling use of a perirectal biodegradable spacer device that can be inserted transperineally under local anaesthetic to improve the quality of treatment and reduce long-term complications.
The trial is a randomised, controlled single-blinded study assessing the impact of this device on reducing rectal toxicity through reducing rectal dose and improving radiotherapy planning.
Members of The Beatson ProSpace Balloon System research team
The Beatson is joined by centres in the USA, Israel, the Netherlands, Portugal and Poland in trialling the system to help improve prostate cancer treatment locally, nationally and internationally and potentially introduce this technique as standard in the near future.
I would like to take this opportunity to thank everyone at The Beatson involved in setting up this trial during these difficult and challenging times and extend my gratitude to R&I colleagues in NHS Greater Glasgow & Clyde Health Board more widely.
For more information on recruitment to this trial, please contact NRS Cancer Research Network Manager – West, Karen Bell at email@example.com or on 0141 301 7206.
Please direct clinical enquiries to firstname.lastname@example.org.